Natco pharma promoter group member Sanjay Nannapaneni has disclosed the sale of 70,000 equity shares of the pharmaceutical company through open market transactions. The sale, conducted between March 9-10, 2026, was valued at ₹7.12 crore and has been disclosed in compliance with SEBI regulations.

Transaction Details

The share sale transaction involved equity shares of ₹2 face value each, executed through the National Stock Exchange (NSE). The disclosure was made on March 11, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Form C of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Shareholding Changes

Following the transaction, Nannapaneni's shareholding in Natco Pharma has been reduced significantly. His stake in the company decreased from 2,26,910 shares to 1,56,910 shares, representing a decline in percentage holding from 0.13% to 0.09%.

Regulatory Compliance

The disclosure demonstrates adherence to SEBI's transparency requirements for promoter group transactions. Nannapaneni, based in Illinois, USA, submitted the required forms to both BSE and NSE, ensuring compliance with insider trading regulations and substantial acquisition norms.

The company's total equity share capital remains unchanged at 17,91,09,870 equity shares of ₹2 each. The transaction represents a routine divestment by a promoter group member through regulated market mechanisms, maintaining transparency in shareholding changes as mandated by securities regulations.

NATCO Pharma Limited has announced the launch of Pomalidomide Capsules, a generic version of Celgene's Pomalyst®, in the United States market. The launch is being executed in partnership with Breckenridge Pharmaceutical, Inc, marking a significant addition to the company's oncology portfolio.

Product Details and Market Opportunity

Pomalidomide Capsules is a thalidomide analogue with multiple therapeutic applications. The product is available in four different strengths and targets substantial market opportunities.

Therapeutic Applications

The medication serves critical treatment needs across multiple patient populations:

• Multiple Myeloma: Treatment for adult patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, with demonstrated disease progression on or within 60 days of completion of the last therapy
• AIDS-related Kaposi Sarcoma: Approved for use after failure of highly active antiretroviral therapy
• HIV-negative Kaposi Sarcoma: Treatment option for adult patients with this condition

Leadership Commentary

Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer of NATCO Pharma Limited, emphasized the strategic importance of this launch: "We are pleased to launch Pomalidomide Capsules in the U.S., this further strengthens our oncology and specialty portfolio in the U.S. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide."

Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, Inc, highlighted the patient access benefits: "Breckenridge's launch of Pomalidomide Capsules delivers a high-quality, affordable generic solution, supported by copay assistance for eligible patients to help reduce treatment delays and ensure continuity of care."

Strategic Significance

The launch represents a major milestone for NATCO Pharma's US operations, particularly in the specialty oncology segment. Based on FDA information, the company believes it has secured 180 days of shared exclusivity for this product. This exclusivity period, combined with the substantial market size of USD 3.20 billion, positions the launch as a significant revenue opportunity.

The partnership with Breckenridge Pharmaceutical demonstrates NATCO's strategy of collaborating with established US partners to enhance market penetration and patient access. The focus on specialty pharmacies and clinics as primary distribution channels aligns with the complex nature of oncology treatments and the need for specialized patient support services.